Treatments and Therapies | Alzheimer's Society

What is lecanemab?

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for NHS at this stage. Here is what we know so far about this breakthrough Alzheimer's drug.

Alzheimer's Society responds to Biogen, Aducanumab results at Clinical Trials on Alzheimer's Disease Conference (CTAD)

Biogen presented their results on Aducanumab, their newest drug for the treatment of Alzheimer's disease at the CTAD conference 2019 in San Diego, USA.

Biogen Inc. will ask U.S. drug regulators to approve new Alzheimer’s drug, Alzheimer’s Society responds

Biogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment, after a new analysis of data from two failed clinical trials showed promising results.

Biogen to halt late-stage trial of Alzheimer’s dug – Alzheimer’s Society comment

US pharmaceuticals company Biogen and its Japanese partner Eisai have announced they will discontinue a global Phase 3 trial for a promising Alzheimer’s disease treatment, aducanumab.

Stem cells and Alzheimer's disease

Exercise-induced hormone may prevent memory loss

New research, published in the Nature journal today, suggests there may be a relationship between the exercise-induced protein hormone irisin and the progression of Alzheimer's disease.

Yale researchers say new compound shows promise in dementia treatment - Alzheimer's Society comment

According to a new study, Yale University researchers have identified a drinkable cocktail of molecules that interferes with a first step of Alzheimer’s disease.

Cholesterol control drug shown to reduce amyloid and brain inflammation

New research has found that the cholesterol control drug, Gemfibrozil, reduces levels of amyloid and brain inflammation in mice.

Potential for new dementia treatment following research trial

New research shows a link between reducing amyloid in the brain and slowing cognitive decline.

Research finds that there could be hope for new dementia treatment

New research shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.

Potential Alzheimer’s disease treatment fails trial

New research shows that a potential new drug to treat Alzheimer’s disease, Lanabecestat, has failed a phase 2/3 trial.

Painkillers may cause harmful side effects for people with dementia

Two new studies have suggest that opioid-based painkillers can cause harmful side effects for people with dementia.

Hormone Replacement Therapy and cognitive health – Alzheimer's Society comment

New research into the cognitive effects of hormone replacement therapy has been presented at Alzheimer’s Association International Conference (AAIC) in Chicago.